The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 344 participants.
Also called NCT01106690
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 344 participants
- Registry
-
NCT01106690
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Finland, France, Germany, Greece, India, Mexico, Spain, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01106690. Randomized; triple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-11 (actual). Results posted on 2013-05-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Pioglitazone
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01106690- Content hash
1ae47c835e784394d71256b9a95375ba88001edaed2752e160cd3fb034f9d431